Please ensure Javascript is enabled for purposes of website accessibility

Wall Street Thinks This Healthcare Stock Could Double Your Money in the Next Year

By Jason Hawthorne – Aug 24, 2021 at 7:10AM

Key Points

  • The early numbers suggested the company would get big fast.
  • Recently, management has had to reassess the role COVID-19 played.
  • Analysts who think the stock could double might need to check their math.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even the median estimate would be a 70% gain.

When a stock nearly triples in its first year as a public company, people tend to notice. That was the case with Inari Medical (NARI -2.06%). The company went from one analyst covering it last year to six -- all but one with a buy rating -- heading into its first quarter earnings report this May. Despite posting robust growth, the stock has gotten crushed in the months since. Its most recent results only worsened the skid.

Now, with the stock down 43% from its highs, the six analysts that cover Inari have a median price target of $119 per share. The highest is predicting $140 -- that's almost double the current price. Let's dig in to see if that's a realistic expectation or if downgrades may be on the horizon.

A clinician helping an elderly person raise their arms.

Image source: Getty Images.

Why were investors so excited?

Nothing gets Wall Street quite as excited as growth. And hypergrowth -- adding more sales per quarter than many companies do in a year -- is especially intoxicating. The stock market is currently full of companies that have parlayed dizzying growth into extremely high valuations. Many won't live up to the hype -- but some will. And that's the draw.

After its initial public offering (IPO) last year, Inari was flying high. Management identified a $3.6 billion market with only 2% of the business currently captured by the company. It was a good story of rapidly growing into an enormous opportunity. That helped the stock to trade at a multiple of 25 to 35 times sales last year.

Quarter Revenue QoQ Revenue Growth Procedures QoQ Procedure Growth
Q4 2020 $48.6 million 26% 4,600 24%
Q3 2020 $38.7 million 52% 3,700 48%
Q2 2020 $25.4 million "modest decline" 2,500 4%

Data source: Inari Medical; qoq=quarter-over-quarter.

Why did they sour on the stock?

Cracks began to show in the company's first quarter earnings release this year. Revenue and procedure growth slowed more than expected. More notably, CEO William Hoffman acknowledged the slowdown in procedures could be the result of fewer COVID-19 patients in the hospital. Until then, the company had consistently pointed to the disease as a hindrance to growth. More of the same followed in the latest quarter, when investors seemed shocked by the numbers.

Quarter Revenue QoQ Revenue Growth Procedures QoQ Procedure Growth
Q2 2021 $63.5 million 11% 5,900 7%
Q1 2021 $57.4 million 18% 5,500 20%

Data source: Inari Medical; yoy=year-over-year.

Wall Street is now left wondering how much of last year's growth was related to the pandemic and how much was due to organic demand. Guidance might offer a clue. And it doesn't bode well for shareholders.

What does the future hold?

Despite the somewhat disappointing results of the second quarter, management still raised full year revenue guidance to between $250 million and $255 million. Raising guidance is usually greeted with cheers and green candles on the stock chart. In this case, it implies slower growth is here to stay.

The company has already posted nearly $121 million in revenue through the first six months of 2021. That means the remaining six months will deliver between $129 million and $134 million. Taken together, growth for the remainder of the year is expected to be about 9% higher than the January to June period. 

If that holds true, the days of hypergrowth are long gone. Despite the implications -- and having already fallen a lot -- the stock still trades at 21 times sales. That's a lofty multiple for a company growing at a pedestrian pace. Either management is being overly conservative or analysts see something the company doesn't. Otherwise, it would make sense for those price targets to come down. 

Perhaps it's the elevenfold increase in COVID-19 cases since mid-June. If procedures do ramp back up, it will be interesting to hear whether management characterizes the outbreak as the brake or accelerant in terms of business. In its short history as a public company, it has been portrayed as both. 

Jason Hawthorne owns shares of Inari Medical, Inc. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inari Medical, Inc. Stock Quote
Inari Medical, Inc.
NARI
$72.31 (-2.06%) $-1.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.